<DOC>
	<DOCNO>NCT02998541</DOCNO>
	<brief_summary>The purpose study determine investigational treatment effective compare placebo PVP-Iodine treatment adult child adenoviral conjunctivitis .</brief_summary>
	<brief_title>Treatment Adenoviral Conjunctivitis With SHP640 Compared Povidone-iodine ( PVP-I ) Placebo</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Inclusion</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Povidone-Iodine</mesh_term>
	<criteria>An understanding , ability , willingness fully comply study procedure restriction ( parent ( ) , guardian , legally authorize representative , applicable ) . Ability voluntarily provide write , sign , date ( personally via parent ( ) , guardian , legallyauthorized representative ( ) inform consent ( assent , applicable ) participate study . Subjects age Visit 1 ( Note : subject &lt; 3 month age Visit 1 must fullterm , ie ≥37 week gestational age birth ) . Have positive AdenoPlus® test Visit 1 least 1 eye . Have clinical diagnosis suspect adenoviral conjunctivitis least 1 eye ( eye AdenoPlus positive eye ) confirm presence follow minimal clinical sign symptom eye : Report presence sign and/or symptoms adenoviral conjunctivitis ≤ 3 day prior Visit 1 Bulbar conjunctival injection : grade ≥1 ( mild ) 04 Bulbar Conjunctival Injection Scale . Watery conjunctival discharge : grade ≥1 ( mild ) 03 Watery Conjunctival Discharge Scale Be willing discontinue contact lens wear duration study . Have Best Corrected Visual Acuity ( BCVA ) 0.60 logMAR good eye measure use Early Treatment Diabetic Retinopathy Study ( ETDRS ) chart . BCVA assess age appropriate method accordance AAP Policy Statement Visual System Assessment Infants , Children , Young Adults Pediatricians ( Donahue Baker 2016 ; American Academy Pediatrics 2016 ) . The policy statement recommend formal vision screen begin 3 year age . VA measurement child age 3 do discretion investigator . If do , child able fixate follow move object , except subject &lt; 2 month age yet develop ability . Subjects &lt; 2 month enrol discretion Investigator . Male , nonpregnant , nonlactating female agree comply applicable contraceptive requirement protocol female nonchildbearing potential . Current recurrent disease could affect action , absorption , disposition investigational product , clinical laboratory assessment , per investigator 's discretion . Current relevant history physical psychiatric illness , medical disorder may make subject unlikely fully complete study , condition present undue risk investigational product procedure . Have know suspected intolerance hypersensitivity investigational product , closely related compound , state ingredient . Prior enrollment FST100 SHP640 clinical study . Subjects employee , immediate family member employee ( directly relate study conduct ) , investigational site . Have history ocular surgical intervention within ≤6 month prior Visit 1 plan period study . Have preplanned overnight hospitalization period study . Have presence intraocular , corneal , conjunctival ocular inflammation ( eg , uveitis , iritis , ulcerative keratitis , chronic blepharoconjunctivitis ) , adenoviral conjunctivitis . Have presence corneal subepithelial infiltrates Visit 1 . Have active history ocular herpes . Have enrollment within ≤30 day Visit 1 , clinical presentation consistent diagnosis ocular allergy , toxic conjunctivitis , nonadenoviral ocular infection ( eg , bacterial , fungal , acanthamoebal , parasitic ) . Neonates infant ( ie . subject less 12 month age ) suspect confirm ( base result test conduct prior screen ) conjunctivitis gonococcal , chlamydial , herpetic chemical origin . Neonates infant ( ie . subject less 12 month age ) whose birth mother sexually transmit disease within 1 month delivery history genital herpes . Presence nasolacrimal duct obstruction Visit 1 ( Day 1 ) . Presence significant ophthalmic condition ( eg , Retinopathy Prematurity , congenital cataract , congenital glaucoma ) congenital disorder ophthalmic involvement could affect study variable . Be know intraocular pressure ( IOP ) steroid responder , know history glaucoma , glaucoma suspect , know history elevate IOP &gt; 21 mmHg . Have know clinically significant optic nerve defect . Have history recurrent corneal erosion syndrome , either idiopathic secondary previous corneal trauma dry eye syndrome ; presence corneal epithelial defect significant corneal opacity Visit 1 . Presence significant , active condition posterior segment require invasive treatment ( eg , intravitreal treatment VEGF inhibitor corticosteroid ) may progress study participation period . Have use topical ocular systemic antiviral antibiotic within ≤7 day enrollment . Have use topical ocular NSAIDs within ≤1 day enrollment . Have use topical ophthalmic steroid last ≤14 day . Have use systemic corticosteroid agent within ≤14 day Day 1 . Stable ( initiated ≥30 day prior enrollment ) use inhale nasal corticosteroid allow , give anticipated change dose duration study . Topical dermal steroid allow except periocular area . Have use noncorticosteroid immunosuppressive agent within ≤14 day Day 1 . Have use topical ophthalmic product , include tear substitute , overthecounter preparation lid scrub , within 2 hour Visit 1 unable discontinue topical ophthalmic product duration study . Use hot cold compress also permit study . Have significant ocular disease ( eg , Sjogren 's syndrome ) uncontrolled systemic disease debilitate disease ( eg , cardiovascular disease , hypertension , sexually transmitted diseases/infections , diabetes cystic fibrosis ) , may affect study parameter , per Investigator 's discretion . Any known history immunodeficiency disorder know active condition predispose immunodeficiency , human immunodeficiency virus , hepatitis B C , evidence active hepatitis A ( antihepatitis A virus immunoglobulin M ) , organ bone marrow transplantation . Within 30 day prior first dose investigational product : Have use investigational product device , Have enrol clinical study ( include vaccine study ) , investigator 's opinion , may impact Shire sponsor study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>